Immune checkpoint (ICP) inhibitors, including PD-1, CTLA4, LAG3, and TIM-3, have potent tumor suppressor effects and can interfere with immune escape; these inhibitors are currently the first-line treatment options for multiple malignancies (Ribas and Wolchok, 2018; Tu et al., 2020). This evidence concerns the gene CTLA4 and neoplasm.